74 related articles for article (PubMed ID: 23099978)
1. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
[TBL] [Abstract][Full Text] [Related]
2. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
[TBL] [Abstract][Full Text] [Related]
3. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
[TBL] [Abstract][Full Text] [Related]
6. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
7. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
8. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
10. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Fallahi P; Mian C; Barollo S; Catania A; Morrone S; Tartaglia F; Mascagni D; Coccaro C; Pepe M; Filippini A; D'Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2015; 29(4):793-803. PubMed ID: 26753639
[TBL] [Abstract][Full Text] [Related]
12. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
13. Is there a treatment advantage when paclitaxel and lovastatin are combined to dose anaplastic thyroid carcinoma cell lines?
Chung YS; Cho S; Ryou HJ; Jee HG; Choi JY; Yoon K; Choi HJ; Lee KE; Suh YJ; Oh SK; Youn YK
Thyroid; 2011 Jul; 21(7):735-44. PubMed ID: 21568723
[TBL] [Abstract][Full Text] [Related]
14. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
VanderPorten EC; Taverna P; Hogan JN; Ballinger MD; Flanagan WM; Fucini RV
Mol Cancer Ther; 2009 Apr; 8(4):930-9. PubMed ID: 19372566
[TBL] [Abstract][Full Text] [Related]
15. New Treatment of Medullary and Papillary Human Thyroid Cancer: Biological Effects of Hyaluronic Acid Hydrogel Loaded With Quercetin Alone or in Combination to an Inhibitor of Aurora Kinase.
Quagliariello V; Armenia E; Aurilio C; Rosso F; Clemente O; de Sena G; Barbarisi M; Barbarisi A
J Cell Physiol; 2016 Aug; 231(8):1784-95. PubMed ID: 26660542
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
[TBL] [Abstract][Full Text] [Related]
18. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
20. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]